A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (PTS) with metastatic colorectal cancer (MCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH PTS

A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (PTS) with metastatic colorectal cancer (MCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH PTS

Show other versions (1)
Bibliographic Details
Main Authors: Trarbach, T, Major, P, Lenz, H, Kerr, D, Pendergrass, K, Douillard, J, Chen, B, Littlewood-Evans, A, Laurent, D, Jacques, C, Van Cutsem, E
Format: Conference item
Published: 2006

Similar Items